Clinical Trial Update: A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy [Phase 2]

View source ↗

Summary

An update on a Phase 2 study evaluating subcutaneous lutikizumab (ABT-981) for hidradenitis suppurativa. The trial assesses disease activity and safety in adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Lutikizumab (ABT-981) (lutikizumab)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: ACTIVE_NOT_RECRUITING